| Indicators | Browse All

Evogene Ltd. (EVGN)

Healthcare | Biotechnology | Rehovot, Israel | NasdaqCM
0.46 USD -0.05 (-9.238%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:25 a.m. EDT

The immediate outlook is severely compromised by a relentless downward price trend over the last two years, with the stock down nearly 98% since 2016 and missing revenue expectations recently. While the balance sheet currently shows a healthy current ratio and manageable debt relative to assets, the business fundamentals are deteriorating sharply, evidenced by negative revenue growth, negative gross margins, and significant operating losses. There is no dividend to provide income, and the lack of analyst coverage combined with a very low-confidence statistical forecast suggests the market is pricing in continued distress rather than a turnaround. The recent price action shows some minor stabilization, but the structural decline in the underlying business quality makes this a high-risk speculative vehicle rather than an investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.120351
AutoETS0.121201
MSTL0.128927
MSTL_1150.137244
AutoTheta0.166253

Forecast horizon: 60 days | Selected: AutoARIMA

Forecast Reliability
Score 23%
H-stat 226.01
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 0.49
Attribute Value
Sector Healthcare
Debt to Equity Ratio 25.419
Revenue per Share 0.214
Market Cap 5,624,941
Forward P/E -0.58
Beta 0.78
Website https://www.evogene.com

Info Dump

Attribute Value
52 Week Change -0.592
Address1 13 Gad Feinstein Street
Address2 Park Rehovot
All Time High 203.9
All Time Low 0.37
Ask 0.6021
Ask Size 2
Average Daily Volume10 Day 3,676,240
Average Daily Volume3 Month 1,693,742
Average Volume 1,693,742
Average Volume10Days 3,676,240
Beta 0.776
Bid 0.3483
Bid Size 2
Book Value -0.244
City Rehovot
Compensation As Of Epoch Date 1,735,603,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 0.4647
Current Ratio 2.79
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 0.5103
Day Low 0.46
Debt To Equity 25.419
Display Name Evogene
Earnings Call Timestamp End 1,779,282,000
Earnings Call Timestamp Start 1,779,282,000
Earnings Timestamp 1,779,280,200
Earnings Timestamp End 1,787,229,000
Earnings Timestamp Start 1,787,229,000
Ebitda -13,334,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.326
Enterprise To Revenue 2.359
Enterprise Value 4,350,811
Eps Current Year -1.7
Eps Forward -0.8
Eps Trailing Twelve Months -2.04
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 972 8 946 6724
Fifty Day Average 0.6166
Fifty Day Average Change -0.15189996
Fifty Day Average Change Percent -0.24635091
Fifty Two Week Change Percent -59.2
Fifty Two Week High 1.5
Fifty Two Week High Change -1.0353
Fifty Two Week High Change Percent -0.69020003
Fifty Two Week Low 0.37
Fifty Two Week Low Change 0.09470001
Fifty Two Week Low Change Percent 0.25594598
Fifty Two Week Range 0.37 - 1.5
Financial Currency USD
First Trade Date Milliseconds 1,287,149,400,000
Float Shares 10,328,837
Forward Eps -0.8
Forward P E -0.580875
Free Cashflow -12,204,750
Full Exchange Name NasdaqCM
Full Time Employees 52
Gmt Off Set Milliseconds -14,400,000
Gross Margins -0.468
Gross Profits -863,000
Has Pre Post Market Data 1
Held Percent Insiders 0.00962
Held Percent Institutions 0.0625
Implied Shares Outstanding 12,104,457
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,721,865,600
Last Split Factor 1:10
Long Business Summary Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Long Name Evogene Ltd.
Market us_market
Market Cap 5,624,941
Market State PRE
Max Age 86,400
Message Board Id finmb_3274115
Most Recent Quarter 1,774,915,200
Net Income To Common -18,540,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 5,836,864
Number Of Analyst Opinions 1
Open 0.5
Operating Cashflow -11,274,000
Operating Margins -9.52096
Payout Ratio 0.0
Phone 972 8 931 1900
Pre Market Change 0.005399972
Pre Market Change Percent 1.162034
Pre Market Price 0.4701
Pre Market Time 1,784,018,224
Previous Close 0.512
Price Eps Current Year -0.27335295
Price Hint 4
Price To Book -1.9045082
Price To Sales Trailing12 Months 3.050402
Profit Margins 0.0
Quick Ratio 2.751
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0473
Regular Market Change Percent -9.23828
Regular Market Day High 0.5103
Regular Market Day Low 0.46
Regular Market Day Range 0.46 - 0.5103
Regular Market Open 0.5
Regular Market Previous Close 0.512
Regular Market Price 0.4647
Regular Market Time 1,783,972,800
Regular Market Volume 282,289
Return On Assets -0.32893002
Return On Equity -1.71754
Revenue Growth -0.863
Revenue Per Share 0.214
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 12,104,457
Shares Percent Shares Out 0.0171
Shares Short 207,368
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 123,199
Short Name Evogene Ltd.
Short Percent Of Float 0.0173
Short Ratio 0.07
Source Interval 15
Symbol EVGN
Target High Price 2.15
Target Low Price 2.15
Target Mean Price 2.15
Target Median Price 2.15
Total Cash 13,054,000
Total Cash Per Share 1.254
Total Debt 2,031,000
Total Revenue 1,844,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.04
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.9266
Two Hundred Day Average Change -0.46189997
Two Hundred Day Average Change Percent -0.49848908
Type Disp Equity
Volume 282,289
Website https://www.evogene.com
Zip 7,638,517